GSBS Student Publications

Title

Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements

UMMS Affiliation

Graduate School of Biomedical Sciences; Department of Internal Medicine III; Department of Cell Biology

Date

5-1-1996

Document Type

Article

Medical Subject Headings

Animals; Blotting, Western; Calcitriol; DNA; Gene Expression Regulation; Macromolecular Substances; Mice; Osteocalcin; Osteopontin; Promoter Regions (Genetics); Rats; Receptors, Calcitriol; Receptors, Retinoic Acid; Retinoid X Receptors; Sialoglycoproteins; Transcription Factors; Transcription, Genetic; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured

Disciplines

Life Sciences | Medicine and Health Sciences

Abstract

Osteocalcin and osteopontin are noncollagenous proteins secreted by osteoblasts and regulated by a complex interplay of systemic and locally produced factors, including growth factors and steroid hormones. We investigated the mechanism by which transforming growth factor-beta (TGF beta) inhibits 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3)-enhanced expression of the osteocalcin (OC) and osteopontin (OP) genes. ROS 17/2.8 cells, in which both genes are expressed, were transfected with reporter constructs driven by native (i.e. wild-type) rat OC and mouse OP promoters. TGF beta abrogated the 1,25-(OH)2D3 enhanced transcription of both the OC and OP genes. The inhibitory TGF beta response for each requires vitamin D response element (VDRE) sequences, although there are additional contributions from proximal basal regulatory elements. These transcriptional effects were further investigated for contribution of the trans-activating factors, which interact with OC and OP VDREs, involving the vitamin D receptor (VDR) and retinoid X receptor (RXR). Gel mobility shift assays show that TGF beta significantly reduces induction of the heterodimers VDR/RXR complexes in 1,25-(OH)2D3-treated ROS 17/2.8 cells. However, Western blot and ligand binding analysis reveal that TGF beta does not affect nuclear availability of the VDR. We also show that activator protein-1 activity is up-regulated by TGF beta; thus, activator protein-1 binding sites in the OC promoter may potentially contribute to inhibitory effects of TGF beta on basal transcription. Our studies demonstrate that the inhibitory action of TGF beta on the 1,25-(OH)2D3 enhancement of OC and OP transcription in osteoblastic cells results from modulations of protein-DNA interactions at the OC and OP VDRE, which cannot be accounted for by changes in VDR protein levels. As OC and OP participate in bone turnover, our results provide insight into the contributions of TGF beta and 1,25-(OH)2D3 to VDR-mediated gene regulatory mechanism operative in bone formation and/or resorption events.

Rights and Permissions

Citation: Endocrinology. 1996 May;137(5):2001-11.

Related Resources

Link to Article in PubMed

Journal Title

Endocrinology

PubMed ID

8612541